Experiences with

Ofatumumab

Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide

This study aims to understand changes in MS symptoms between doses for people with MS who are treated with ocrelizumab (Ocrevus) or ofatumumab (Kesimpta). We’re conducting this study with the pharmaceutical company Novartis and their consultant STATLOG Inc.

A small study follows women who did get pregnant while taking it. https://www.optometryadvisor.com/general-medicine/ofatumumab-use-women-relapsing-ms-what-are-the-pregnancy-outcomes/#xd_co_f=ZGZjMWVmMDgtYmZiMi00OTQwLTk4ZDYtMWIxNzE4NmY2NzE5~

In the pivotal studies for patients with R/R CLL, idelalisib was combined with rituximab vs rituximab alone; however, duvelisib was studied as monotherapy vs ofatumumab.

I’ve been on Rituximab for a few years now (with ofatumumab in between before it was pulled in IV form). I always have infusion reactions, even with pre meds! Ugh, it’s so frustrating 😭 I had an infusion Friday and I will say this has by far been the best infusion I’ve had to date.

I was previously on ofatumumab IV until the pharmaceutical company discontinued it and only offers it as kesimpta for home sub q injection (for 5x the price 🤔). My doctor was like there’s no way you can do that at home because of your reactions.

In addition, they may experience: • Treatment-related immunodeficiency (such as that resulting from anti-CD20 monoclonal antibody treatment such as Rituximab (Mabthera/Rituxan), Obinutuzumab (Gazyva) or ofatumumab (Arzerra) In a recent study, ‘individual risk factors associated with a poor prognosis

If you are in treatment, or have had treatment with Rituximab, Obinutuzumab, Ofatumumab or other anti-CD20 monoclonal antibodies within the past 6 months, you are less likely to produce an antibody response to a vaccination, but it is expected that you will still develop some T-cell based immunity response

My dr switched me to ofatumumab infusions, which I know is a pretty new medication. So far, I’m doing well, was able to return back to work a few months after my diagnosis (nurse). I’m just a bit scared for the future!

Hello everyone, I found out yesterday about a new DMT called kesimpta (ofatumumab). Like Ocrevus it hits the B cell. The difference is its a once a month self administered injection. Im posting a link to the website for those who are interested.

Other Type I mAbs include ocrelizumab [OCR] and ofatumumab [OFA;]. Type II mAbs such as obinutuzumab (OBZ; Gazyva) and tositumomab (Bexxar) exhibit low CDC activity and lack the ability to localize CD20 into lipid rafts but induce higher levels of direct cell death.

My previous treatments were Rituxan, in my 10th month after diagnosis, then Idealisib and Ofatumumab in a clinical trial, which gave me 39 months of no advancement of disease.

I presume the biggest problems here were caused by Ofatumumab, although Zydelig is not a well tolerated drug. I was great for about 39 months until I started having some serious complications and bleeding events and had to have gall bladder removed.

Furthermore, treatment with the PI3K inhibitor led to a superior median progression-free survival (PFS) compared with ofatumumab (Arzerra) while producing rapid and durable responses in heavily pretreated patients.

June 2012 Bendamustine and Ofatumumab, but changed to Rituxan. 2014 to date IVIG. Jan 2017 Ibrutinib. Trisomy 12 (NOTCH 1 and SF3B1 unmutated), IgVH mutated, ZAP70 -ve, CD38 -ve.

June 2012 Bendamustine and Ofatumumab, but changed to Rituxan. 2014 to date IVIG. Jan 2017 Ibrutinib. Trisomy 12 (NOTCH 1 and SF3B1 unmutated), IgVH mutated, ZAP70 -ve, CD38 -ve.

I have CLL and had my first FCR chemo except not Rituximab but Ofatumumab. Everything went well but since 10 days I have extreme high fever 39,9-40 degrees and itchy everywhere on my body and under my feet and hands.

In sub-group analyses, researchers found duvelisib worked just as well as ofatumumab among the hardest-to-treat cases, including those patients with p17 deletion or p53 abnormalities, who have few available therapeutic options.

Patients were exposed to ofatumumab for a median duration of 5 months (range, <0.1 to 6). The ORR was 78% with duvelisib versus 39% with ofatumumab. - Len P.S. It seems the drug companies love to choose words that are difficult to pronounce Copiktra really???

Verastem’s duvelisib was seen to outperform Arzerra (ofatumumab) in a Phase 3 trial of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the company announced.